Perspectum

Perspectum Ltd. is a medical-technology company headquartered in Oxford, England, whose brand is associated with software for extracting quantitative information from magnetic resonance imaging scans. The company originated from research involving the University of Oxford and was founded in 2012 by Rajarshi Banerjee, Matthew Robson, Stefan Neubauer, and Michael Brady. Its work sits at the intersection of clinical imaging, biomedical research, artificial intelligence and software-enabled decision support. The company’s principal area of activity has been quantitative liver imaging. Rather than treating an MRI scan solely as a visual record for radiological interpretation, Perspectum’s platforms are designed to derive numerical measurements from tissue characteristics. These measurements can include liver fat, iron and fibro-inflammatory change. The approach is intended to support more consistent assessment of disease, monitoring over time, clinical-trial research and the development of imaging biomarkers that may reduce reliance on invasive procedures in selected pathways. Perspectum introduced LiverMultiScan as a research device in Europe and the United States in 2014. The product subsequently received clearance from the United States Food and Drug Administration in 2016. LiverMultiScan uses MRI-derived biomarkers including corrected T1 mapping, proton-density fat fraction and T2* measurements to characterize aspects of liver tissue. Research and health-economic studies have examined its potential use in conditions such as autoimmune hepatitis and metabolic dysfunction-associated steatotic liver disease, including as an alternative or complement to liver biopsy in some care pathways. The technology is also relevant to pharmaceutical development, where standardized imaging biomarkers can help evaluate disease progression and treatment response. The company has expanded beyond a single liver-imaging product. MRCP+ has been studied for quantitative evaluation of the biliary system, including applications involving primary sclerosing cholangitis. Hepatica is a liver-surgery decision-support tool that received FDA clearance in 2021. During the COVID-19 pandemic, Perspectum’s CoverScan platform was used in research examining organ impairment after infection, reflecting a broader interest in multi-organ imaging rather than a focus limited to hepatology. Perspectum’s business model combines regulated medical software, clinical research services and imaging-technology development. Its potential customers and collaborators include hospitals, academic research groups, pharmaceutical companies and organizations involved in clinical trials or health-system planning. The company has also pursued work on imaging biomarkers for drug development in non-alcoholic steatohepatitis, receiving an FDA grant in 2019 to support evaluation in that field. In 2023, Perspectum secured Series C funding, although the available reference material does not specify the amount, investors or valuation. In 2024, it entered a collaboration with the London Institute for Healthcare Engineering at King’s College London on medical-imaging research related to metabolic disease and cancer. The collaboration illustrates the company’s continuing expansion from liver-focused tools toward wider metabolic and oncological applications. The brand is positioned as a specialist medical-imaging and digital-health company whose differentiation rests on quantitative MRI biomarkers, clinical validation and translation of academic imaging research into regulated software products. It remains an active private company; no public listing, ticker or parent organization is identified in the supplied sources.

Perspectum emerged from research connected with the University of Oxford and was established in 2012 by Rajarshi Banerjee, Matthew Robson, Stefan Neubauer and Michael Brady. The founders combined clinical, scientific and imaging expertise around the idea that MRI could provide more than qualitative pictures. By extracting reproducible measurements from scans, quantitative MRI could potentially improve the assessment of disease, help clinicians monitor change and give researchers standardized endpoints for clinical studies. The company’s early commercial and research focus was the liver. In 2014, Perspectum introduced LiverMultiScan as a research device in Europe and the United States. The platform was developed to characterize liver tissue using MRI-derived biomarkers rather than requiring a biopsy for every assessment. Its measurements have included corrected T1, proton-density fat fraction and T2* values, which are associated with different tissue characteristics such as fibro-inflammatory change, fat and iron. LiverMultiScan reached an important regulatory milestone in 2016 when it received clearance from the US Food and Drug Administration. The clearance helped establish Perspectum as a developer of regulated medical-imaging software and supported the use of its technology in clinical and research contexts. Subsequent studies and health-economic analyses investigated the role of quantitative MRI in diseases including autoimmune hepatitis and metabolic dysfunction-associated steatotic liver disease. These studies considered whether imaging could complement or, in selected pathways, reduce dependence on invasive liver biopsy. Perspectum’s research agenda broadened during the late 2010s. In 2019, the company received an FDA grant supporting evaluation of imaging biomarkers for drug development in non-alcoholic steatohepatitis. This work reflected the importance of reliable, scalable endpoints in pharmaceutical research, where imaging may be used to assess disease status or response to treatment without repeated invasive sampling. The company subsequently developed additional products and research applications. MRCP+ was studied as a quantitative tool for assessing the biliary system, including in primary sclerosing cholangitis. Hepatica, a liver-surgery decision-support product, received FDA clearance in 2021. During the COVID-19 pandemic, CoverScan was used in research examining organ impairment after infection, extending Perspectum’s imaging approach from liver disease to broader multi-organ assessment. Perspectum secured Series C funding in 2023. The supplied sources do not provide the financing amount, investor list or precise use of proceeds, but the round marked continued external support for the company’s product and research development. In 2024, Perspectum began a collaboration with the London Institute for Healthcare Engineering at King’s College London. The collaboration addressed medical-imaging research related to metabolic disease and cancer, consistent with the company’s move toward broader applications of quantitative imaging. By the period covered by the supplied material, Perspectum remained an active Oxford-based medical-technology company. Its identity is built around software rather than MRI hardware: the company processes images generated by MRI systems and converts them into quantitative measurements, reports and decision-support outputs. Its activities span regulated clinical products, academic collaborations, clinical research and drug-development support. No evidence in the supplied sources establishes a public stock listing, acquisition by a parent company or a change of corporate control.

• 2026

  Listed in The Sunday Times Tech 100

  [1]Perspectumen.wikipedia.org

  Perspectum was reported at number 36 in The Sunday Times Tech 100 ranking in January 2026.

• 2024

  King’s College London research collaboration

  [1]Perspectumen.wikipedia.org

  Perspectum collaborated with the London Institute for Healthcare Engineering on imaging research involving metabolic disease and cancer.

• 2023

  Series C funding secured

  [1]Perspectumen.wikipedia.org

  Perspectum secured Series C financing; the supplied material does not state the amount or investors.

• 2021

  Hepatica receives FDA clearance

  [1]Perspectumen.wikipedia.org

  Hepatica, a liver-surgery decision-support tool, received clearance from the US FDA.

• 2019

  FDA grant for NASH imaging-biomarker research

  [1]Perspectumen.wikipedia.org

  Perspectum received an FDA grant to support evaluation of imaging biomarkers for drug development in non-alcoholic steatohepatitis.

• 2016

  US FDA clearance for LiverMultiScan

  [1]Perspectumen.wikipedia.org

  LiverMultiScan received clearance from the United States Food and Drug Administration.

• 2014

  LiverMultiScan introduced as a research device

  [1]Perspectumen.wikipedia.org

  Perspectum introduced LiverMultiScan in Europe and the United States as a research device for quantitative liver MRI.

• 2012

  Company founded

  [1]Perspectumen.wikipedia.org

  Perspectum was founded by Rajarshi Banerjee, Matthew Robson, Stefan Neubauer and Michael Brady, researchers and clinicians associated with the University of Oxford.

A specialist medical-imaging and digital-health company focused on converting MRI scans into quantitative biomarkers and clinically useful decision-support information.

• Quantitative liver MRI software · 2014

  LiverMultiScan

  LiverMultiScan is Perspectum’s best-known quantitative liver-imaging platform. It analyzes MRI data to generate measurements associated with liver fat, iron and fibro-inflammatory change. Its biomarker approach includes corrected T1 mapping, proton-density fat fraction and T2* measurements. The product has been studied in liver-disease pathways including autoimmune hepatitis and metabolic dysfunction-associated steatotic liver disease, as well as in health-economic and pharmaceutical research. It was introduced as a research device in 2014 and received US FDA clearance in 2016.

• Quantitative biliary-system MRI software

  MRCP+

  MRCP+ is an imaging platform designed to support quantitative assessment of the biliary system using magnetic resonance cholangiopancreatography data. Research has examined its use in conditions such as primary sclerosing cholangitis. The supplied sources establish the product and its research application but do not provide a detailed commercial launch date or current regulatory status.

• Liver-surgery decision-support software · 2021

  Hepatica

  Hepatica is a decision-support tool for liver surgery. It is part of Perspectum’s effort to apply quantitative imaging to treatment planning and clinical decision-making rather than limiting analysis to disease measurement. Hepatica received clearance from the US FDA in 2021. The supplied material does not specify the precise clinical indications, deployment model or commercial availability.

• Multi-organ MRI platform

  CoverScan

  CoverScan is a multi-organ imaging platform associated with research into organ impairment following COVID-19 infection. Its use during the pandemic demonstrated how Perspectum’s quantitative-imaging methods could be applied beyond the liver. The supplied references describe research use but do not establish a specific commercial launch date or current regulatory status.

• 2024

  Expansion of academic imaging researchStrategy

  Background

  Perspectum had developed applications extending from liver imaging to metabolic and multi-organ disease research.

  Action taken

  The company entered a collaboration with the London Institute for Healthcare Engineering at King’s College London.

  Aftermath

  The collaboration focused on medical-imaging research related to metabolic disease and cancer, broadening the company’s research network and application scope.

  Source

• 2023

  Series C financingStrategy

  Background

  Perspectum continued developing regulated imaging products and research applications in liver disease, metabolic disease and multi-organ imaging.

  Action taken

  The company secured Series C funding.

  Aftermath

  The supplied reference confirms the financing but does not report its amount, investors or detailed deployment.

  Source

• 2014

  Introduction of LiverMultiScanProduct launch

  Background

  Perspectum was developing quantitative MRI applications for liver disease and research, with an emphasis on extracting standardized biomarkers from scans.

  Action taken

  The company introduced LiverMultiScan as a research device in Europe and the United States.

  Aftermath

  LiverMultiScan later received US FDA clearance in 2016 and became the company’s principal liver-imaging offering.

  Source

• 2026

  Perspectum appears in The Sunday Times Tech 100[1]Perspectumen.wikipedia.org

  Other

  Perspectum was reported as number 36 in The Sunday Times Tech 100 ranking in January 2026.

• 2024

  Perspectum collaborates with King’s College London engineering institute[1]Perspectumen.wikipedia.org

  Other

  Perspectum entered a collaboration with the London Institute for Healthcare Engineering at King’s College London on medical-imaging research involving metabolic disease and cancer.

• 2023

  Perspectum secures Series C funding[1]Perspectumen.wikipedia.org

  Other

  The company raised Series C funding to support its medical-imaging and digital-health activities. The supplied reference does not identify the financing amount or participating investors.

• 2019

  Perspectum receives FDA grant for NASH imaging-biomarker evaluation[1]Perspectumen.wikipedia.org

  Other

  Perspectum received a grant from the US Food and Drug Administration to support evaluation of imaging biomarkers for drug development in non-alcoholic steatohepatitis.

1. 1Perspectumen.wikipedia.org
2. 2Perspectum official websiteperspectum.com
3. 3Perspectum announces partnership with Precious Medical Centreksl.com
4. 4Perspectum Appoints Annalisa Jenkins, MBBS, FRCP to Board of Directorsfinanznachrichten.de
5. 5Perspectum Closes $36M Financing Round co-led by Blue Venture Fund and HealthQuest Capitalbiospace.com